Blueprint Medicines Corporation (BIT:1BPMC)
90.62
+2.56 (2.91%)
At close: May 12, 2025
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $149.41M USD in the quarter ending March 31, 2025, with 55.45% growth. This brings the company's revenue in the last twelve months to $562.12M, up 99.19% year-over-year. In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth.
Revenue (ttm)
$562.12M
Revenue Growth
+99.19%
P/S Ratio
11.20
Revenue / Employee
$866.13K
Employees
649
Market Cap
5.83B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 508.82M | 259.44M | 104.04% |
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Intesa Sanpaolo | 25.42B |
UniCredit | 23.99B |
Enel SpA | 78.35B |
Ferrari | 6.88B |
Assicurazioni Generali | 55.30B |
Eni S.p.A. | 90.96B |
Leonardo S.p.a. | 17.76B |
Stellantis | 156.88B |